DK1924585T3 - Hidtil ukendt krystallinsk for af et pyridazino[4,5-b]indol-derivat - Google Patents

Hidtil ukendt krystallinsk for af et pyridazino[4,5-b]indol-derivat

Info

Publication number
DK1924585T3
DK1924585T3 DK06813757.9T DK06813757T DK1924585T3 DK 1924585 T3 DK1924585 T3 DK 1924585T3 DK 06813757 T DK06813757 T DK 06813757T DK 1924585 T3 DK1924585 T3 DK 1924585T3
Authority
DK
Denmark
Prior art keywords
pyridazino
hitherto
lining
crystalline
indole derivative
Prior art date
Application number
DK06813757.9T
Other languages
English (en)
Inventor
William L Rocco
John D Higgins
Original Assignee
Sanofi Aventis Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546937&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1924585(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Us Llc filed Critical Sanofi Aventis Us Llc
Application granted granted Critical
Publication of DK1924585T3 publication Critical patent/DK1924585T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK06813757.9T 2005-08-29 2006-08-24 Hidtil ukendt krystallinsk for af et pyridazino[4,5-b]indol-derivat DK1924585T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71215305P 2005-08-29 2005-08-29
PCT/US2006/033254 WO2007027525A1 (en) 2005-08-29 2006-08-24 Novel crystalline form of a pyridazino [4 , 5-b] indole derivative

Publications (1)

Publication Number Publication Date
DK1924585T3 true DK1924585T3 (da) 2012-02-27

Family

ID=37546937

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06813757.9T DK1924585T3 (da) 2005-08-29 2006-08-24 Hidtil ukendt krystallinsk for af et pyridazino[4,5-b]indol-derivat

Country Status (32)

Country Link
US (1) US7683062B2 (da)
EP (1) EP1924585B1 (da)
JP (1) JP5063600B2 (da)
KR (2) KR20080050577A (da)
CN (1) CN101253176B (da)
AR (1) AR057099A1 (da)
AT (1) ATE531717T1 (da)
AU (1) AU2006285142B2 (da)
BR (1) BRPI0615259A2 (da)
CA (1) CA2619284C (da)
CR (1) CR9723A (da)
CY (1) CY1112317T1 (da)
DK (1) DK1924585T3 (da)
EA (1) EA014164B1 (da)
EC (1) ECSP088209A (da)
ES (1) ES2375841T3 (da)
HK (1) HK1123794A1 (da)
HR (1) HRP20120073T1 (da)
IL (1) IL189276A (da)
MA (1) MA30000B1 (da)
NO (1) NO20081365L (da)
NZ (1) NZ566087A (da)
PL (1) PL1924585T3 (da)
PT (1) PT1924585E (da)
RS (1) RS52318B (da)
SI (1) SI1924585T1 (da)
TN (1) TNSN08059A1 (da)
TW (1) TW200813060A (da)
UA (1) UA91716C2 (da)
UY (1) UY29771A1 (da)
WO (1) WO2007027525A1 (da)
ZA (1) ZA200801890B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004311544A1 (en) * 2003-11-17 2005-07-21 Merck & Cie Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
ES2370829T3 (es) * 2004-06-02 2011-12-23 Sandoz Ag Producto intermedio de meropenem en forma cristalina.
EP1928826B1 (en) * 2005-09-21 2013-04-24 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
EA014905B1 (ru) * 2005-10-31 2011-02-28 Янссен Фармацевтика Н.В. Новый способ получения пиперазинильных производных бензамида
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
BRPI0717394A2 (pt) * 2006-10-27 2013-10-15 Signal Pharm Llc Forma cristalina, composição farmacêutica, forma de dosagem unitária única, método para tratar ou prevenir uma doença ou condição, e, processo para preparar um composto
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
BRPI0917519A2 (pt) * 2008-08-18 2015-08-04 Sanofi Aventis Us Llc Processo para preparacao de um polimorfo de 7-cloro-n,n,5-trimetil-4-oxo-3-fenil-3,5-di-hidro-4h-pir idazino[4,5-b]indol-1-acetamida
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2012030957A2 (en) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
CN103930419B (zh) * 2011-09-30 2016-06-01 广东东阳光药业有限公司 阿齐沙坦的晶型及其制备方法
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766823B1 (fr) * 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
FR2829939B3 (fr) 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
US20050220881A1 (en) 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
KR20130087059A (ko) 2013-08-05
CR9723A (es) 2008-06-18
NZ566087A (en) 2011-03-31
CA2619284C (en) 2014-04-29
HRP20120073T1 (hr) 2012-07-31
JP5063600B2 (ja) 2012-10-31
JP2009506116A (ja) 2009-02-12
PT1924585E (pt) 2012-01-19
CY1112317T1 (el) 2015-12-09
ES2375841T3 (es) 2012-03-06
IL189276A0 (en) 2008-08-07
ATE531717T1 (de) 2011-11-15
HK1123794A1 (en) 2009-06-26
AR057099A1 (es) 2007-11-14
TW200813060A (en) 2008-03-16
MA30000B1 (fr) 2008-12-01
EA200800716A1 (ru) 2008-08-29
UY29771A1 (es) 2007-03-30
BRPI0615259A2 (pt) 2011-05-17
WO2007027525A1 (en) 2007-03-08
CN101253176B (zh) 2012-04-18
TNSN08059A1 (en) 2009-07-14
US7683062B2 (en) 2010-03-23
US20080139569A1 (en) 2008-06-12
AU2006285142A1 (en) 2007-03-08
ZA200801890B (en) 2009-11-25
RS52318B (en) 2012-12-31
EA014164B1 (ru) 2010-10-29
EP1924585B1 (en) 2011-11-02
ECSP088209A (es) 2008-06-30
CA2619284A1 (en) 2007-03-08
EP1924585A1 (en) 2008-05-28
UA91716C2 (ru) 2010-08-25
PL1924585T3 (pl) 2012-08-31
IL189276A (en) 2012-07-31
SI1924585T1 (sl) 2012-09-28
KR20080050577A (ko) 2008-06-09
AU2006285142B2 (en) 2012-06-14
NO20081365L (no) 2008-04-03
CN101253176A (zh) 2008-08-27

Similar Documents

Publication Publication Date Title
DK1924585T3 (da) Hidtil ukendt krystallinsk for af et pyridazino[4,5-b]indol-derivat
HK1100410A1 (en) Indole derivatives having piperidine rings
DK1924151T3 (da) Oral frigivelsessystem med styret frigivelse
DK1883451T3 (da) Substituerede indolforbindelser med NOS-hæmmende virkning
ATE501119T1 (de) Entzündungshemmende indol-derivate
MA28347A1 (fr) Dérivés de quinoléine substitués
DK1737461T3 (da) Carbolin-derivater til inhibering af angiogenese
PL2067108T3 (pl) Lokalizowanie węzłów odniesienia do pozycjonowania
DK1710241T3 (da) Intermediatforbindelser til fremstilling af trans-5-chlor-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrol
GB0419481D0 (en) Isoindolin-1-one derivatives
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1874766T3 (da) Krystallinsk form af en quinolinon-carboxamid-forbindelse
EP1893625A4 (en) PROCESS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES
DK2213654T3 (da) Fremgangsmåde til fremstilling af 2-amino-5-brombenzamid derivater
DK1838683T3 (da) Fremgangsmåde til fremstilling af [1,4,5]-oxadiazepinderivater
IL190729A0 (en) Methods for preparing glutamic acid derivatives
DK1784183T3 (da) Fremgangsmåder til fremstilling af isothiazolderivater
GB0405334D0 (en) Method for exchanging signals via nodes
EP1919871A4 (en) PROCESS FOR SYNTHESIS OF CHINOLINE DERIVATIVES
DK1682541T3 (da) Fremgangsmåde til fremstilling af tiotropiumsalte
DK1888613T3 (da) Fremgangsmåde til fremstilling af thiophenglycosidderivater
EP1880995A4 (en) METHOD OF SYNTHESIZING AN INDOLE DERIVATIVE COMPRISING A PIPERIDINE CYCLE
EP1849766A4 (en) BETA-BENZYLOXYASPARTICAL ACID DERIVATIVE HAVING TWO SUBSTITUENTS ON BENZENIC CORE
GB0521726D0 (en) Methods for the preparation of organic compounds
GB0521728D0 (en) Methods for the preparation of organic compounds